Table 2.
Primary and secondary endpoints for ixekizumab compared with other anti-IL-17 and anti-IL-23 agents at the most efficacious dosing regimens
| Regimen | Weeks | PASI 75, % | sPGA 0-1, % | DLQI 0-1, % | Reference |
|---|---|---|---|---|---|
| Tildrakizumab 200 mg | 16 | 72.1 | 74.4 | 55.8 | 16 |
| Guselkumab 200 mg | 16 | 81.0 | 83.3 | 70.3 | 17 |
| Ustekinumab 90 mg | 12 | 75.7 | 73.5 | 56.4 | 18 |
| Brodalumab (210 mg pooled data) | 12 | 85.3 | 78.6 | – | 21, 22 |
| Secukinumab (300 mg pooled data) | 12 | 83.2 | 70.2 | 66.2 | 21, 37 |
| Ixekizumab (80 mg Q2W pooled data) | 12 | 88.7 | 81.8 | 66.4* | 32 |
Notes: The above data were tabulated from independent studies that were not conducted in a head-to-head manner.
*
Tabulated from UNCOVER-2 and UNCOVER-3 only.
Abbreviations: DLQI, Dermatology Life Quality Index; IL, interleukin; PASI, Psoriasis Area and Severity Index; Q2W, every 2 weeks; sPGA, Static Physician Global Assessment.